Financials
Financial year 2024
Worth noting
- More debts than assets in the latest financial year.
- A loss two years in a row.
- Little cash and receivables against the short-term debts.
Revenue
€ 1.5 million
▲ 44% vs 2023
Profit
Caution€ -6.2 million
▲ 81% vs 2023
Debts
High€ 36.3 million
▲ 28% vs 2023
IMCYSE from Liège, company number BE0828385542, closed financial year 2024 with a result of € -6.2 million after tax. For that financial year IMCYSE recorded revenue of € 1.5 million and equity of € -33.4 million. Compared with financial year 2023, the result moved from € -32.8 million to € -6.2 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 13, 2024.
What happened at IMCYSE?
What happened at IMCYSE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: loss of € 6.2 million. Source: NBB ↗
- Roman AYDOGDU became a director. NBB
- BIOPHARMA MANAGEMENT AND CONSULTING SRL stepped down as director. NBB
- NOSHAQ PARTNERS SCRL stepped down as director. NBB
- SPARAXIS SA stepped down as director. NBB
- Vincent BRICHARD stepped down as director. NBB
- SVR INVEST SRL stepped down as director. NBB
- TOMTAA UG stepped down as director. NBB
In short
From € 18.6 million loss in 2021 to € 6.2 million loss in 2024.
Paid € 2 million in corporate taxes since 2021.
A new publication or filing at IMCYSE? We notify you, reason included.
Follow IMCYSENeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind IMCYSE is Roman AYDOGDU. It owns 100% of Imcyse US, Inc itself.
Directors
According to the 2024 annual accounts
Roman AYDOGDU
Liquidator
since 2024
BIOPHARMA MANAGEMENT AND CONSULTING SRL
Director · represented by Denis BEDORET
Also active at: Ncardia Holding, EXOTHERA
since 2021 · until 2024
Director · represented by Hugues WALLEMACQ
Also active at: CAUTION MUTUELLE DES METIERS ET NEGOCES, Fonderies J. Marichal Ketin et Cie, DARDENNE +174 more
since 2019 · until 2024
Director · represented by Christine FRANSSEN
Also active at: C.P. Bourg, A.M.B., Jean Goldschmidt International +228 more
since 2019 · until 2024
since 2021 · until 2024
Director · represented by Stijn VANROMPAY
Also active at: SILVERLINE PROPERTIES, SILVERLINE DEVELOPMENT, ARTEVA PARTNERS
since 2019 · until 2024
TOMTAA UG
Chairman of the board · represented by Thomas TAAPKEN
since 2019 · until 2024
Director · represented by Stefan Yee
Also active at: AED Rent, HELIVENTURE FTO, WIISH +10 more
since 2019 · until 2024
Establishments
Establishment units
Physical locations of this company
Avenue Pré-Aily 14
4031 Liège
Avenue de l'Hôpital 1
4000 Liège
Active since 18 July 2013
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
OVH, FR
DNS
OVH DNS
Domain
Domain
imcyse.com
Registered
2010-11-10
Registrar
OVH, SAS
Expires
2026-11-10
Website info
Features
Security
Network
Details
- Company number
- 0828.385.542
- VAT number
- BE 0828.385.542
- Registered office
- Avenue Pré-Aily 14, 4031 Liège
- Names & denominations
- IMCYSE
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Vrijwillige ontbinding – vereffening
- Start date
- 10 August 2010
- Peppol
- Active · Active since 14 Apr 2026
- Contact
- imcyse.com
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied